CDC Publishes Study on Allergic Reactions to COVID-19 Vaccine


Important note: This article is intended for those who understand vaccines as critical to maintaining their health and that of their families. It is NOT intended for those who are anti-vaccine and as such is NOT intended to foster a discussion on the merits of vaccines in this forum. It is also NOT intended to foster a discussion of the lethality of COVID-19 or the need for civic action to limit the spread of the disease.

The Centers for Disease Control (CDC) published a study yesterday of anaphylactic reactions that occurred during December 14-23, 2020 showing that such reactions are exceedingly rare.

The full CDC release can be found here; here are the highlights from the report:

  • 1,893,360 initial doses of the Pfizer vaccine were administered during the period;
  • 4,393 adverse reactions were reported. Of those, 21 were identified as anaphylactic reactions and 175 were identified for further review as possible allergic reactions.
  • Of the 175 possible allergic reactions, 86 were deemed non-anaphylactic, 61 were considered non-allergic reactions and 7 are still under review;
  • 17 of the 21 anaphylactic reactions were in people who had documented histories of allergies or allergic reactions;
  • Follow-up information was available for 20 of the 21 people who suffered anaphylaxis. All of them had recovered/been released.
Click to visit sponsor

The 21 incidents of anaphylaxis translate to a rate of 11.1 anaphylactic reactions per 1 million doses.

The CDC’s National Center for Immunization and Respiratory Diseases indicates the rate of anaphylaxis for flu vaccine is approximately 1.3 anaphylactic reactions per 1 million doses.

Said Dr Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases:

I guess you could mathematically say that’s 10 times the amount. But I think that misses the point because it’s still exceedingly rare. The risk from COVID and poor outcomes from COVID is still more than their risk of a severe outcome from the vaccine.

Click to visit sponsor

An excerpt from the study states:

Mortality from COVID-19 in populations at high risk is substantial (10), and treatment options are limited. Widespread vaccination against COVID-19 with highly effective vaccines represents an important tool in efforts to control the pandemic. CDC and FDA will continue to monitor for adverse events, including anaphylaxis, after receipt of COVID-19 vaccines and will regularly assess the benefits and risks of vaccination in the context of the evolving epidemiology of the pandemic.

Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.